A Phase I Study of Vincristine, Irinotecan, Temozolomide and Bevacizumab (Vitb) in Pediatric Patients with Relapsed Solid Tumors

• Rajkumar Venkatramani ,

  * E-mail: rvenkatramani@chla.usc.edu

  Affiliations Division of Hematology/Oncology, Children’s Hospital Los Angeles, Los Angeles, California, United States of America, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America

  ⨯
• Marcio Malogolowkin,

  Affiliation Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, United States of America

  ⨯
• Tom B. Davidson,

  Affiliation Department of Pediatrics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, United States of America

  ⨯
• William May,

  Affiliations Division of Hematology/Oncology, Children’s Hospital Los Angeles, Los Angeles, California, United States of America, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America

  ⨯
• Richard Sposto,

  Affiliations Division of Hematology/Oncology, Children’s Hospital Los Angeles, Los Angeles, California, United States of America, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America

  ⨯
• Leo Mascarenhas

  Affiliations Division of Hematology/Oncology, Children’s Hospital Los Angeles, Los Angeles, California, United States of America, Department of Pediatrics, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America

  ⨯